Compare Novavax Inc (NVAX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.59 with a neutral daily change. Technical indicators show a bullish trend from moving averages, though oscillators are neutral to slightly overbought. The fund has gained attention for its income appeal, with a 3.4% dividend yield and strong performance, including a 55% total return since prior coverage, as noted by Seeking Alpha on 2026-08-02. Recent institutional buying, such as by Barry Investment Advisors on 2026-08-10, underscores confidence.

The outlook is positive, driven by global diversification and high dividend growth, with Vanguard projecting international stocks to outperform U.S. equities over the next decade. Risks include currency fluctuations and economic volatility in international markets. Analyst sentiment is bullish, supported by the fund's defensive yield and institutional inflows.